Providence, RI – MedMates, RI’s Life Sciences industry network group, announced the appointment of Dr. Patrice M. Milos to its board of directors.
Dr. Milos is the president/CEO and co-founder of Medley Genomics, a life sciences company dedicated to addressing the challenges of genomic heterogeneity in the diagnosis and treatment of complex diseases. Initially focused in oncology, Medley provides unique ‘molecular fingerprints’ of a patient’s cancer enabling individualized diagnosis and optimal treatment.
“Patrice is a pioneer at the interface of genomics and medicine and brings this highly innovative and specialized area of expertise to our board,” said Carol Malysz, executive director, MedMates. “She has dedicated her life to improving patients’ lives through her passion for personalized healthcare and the application of innovative science and technologies to understand human disease.”
“I am honored to serve on the MedMates board,” said Dr. Milos, “This is a key time for Life Sciences in Rhode Island and holds the promise of significant growth and economic impact for our state, and I am pleased to be a part of the organization at the forefront of driving this collaborative effort.”
Prior to her current position, Dr. Milos was president/CEO at Claritas Genomics in Cambridge, MA and held senior executive roles at Pfizer Inc. She serves on the European Commission ULTRAPLACAD External Advisory Board and is an Advisor to Pharmagenetix and SeqLL. Dr. Milos also serves on the BCH Technology Advisory Board, is an active NIH SBIR grant reviewer and has served on the National Advisory Council for NIH’s Human Genome Research Institute. She sits on several journal editorial boards and has published extensively in genomic sciences. Dr. Milos conducted post-doctoral fellowships at Brown University and Harvard University and earned her PhD at Rensselaer Polytechnic Institute in Troy, NY.